[
    [
        {
            "time": "2018-11-06",
            "original_text": "Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know",
            "features": {
                "keywords": [
                    "Pfizer",
                    "stock sinks",
                    "market gains"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-11-05",
            "original_text": "MARKETS: Pharma stocks making moves ahead of midterms",
            "features": {
                "keywords": [
                    "pharma stocks",
                    "midterms"
                ],
                "sentiment_score": 0.4,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-11-07",
            "original_text": "Eli Lilly's Conservative Pricing Offers Protection From Political Pressure",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "conservative pricing",
                    "political pressure"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-11-08",
            "original_text": "Beaten-Down Pharma ETFs to Buy Post Q3 Results",
            "features": {
                "keywords": [
                    "beaten-down",
                    "ETFs",
                    "Q3 results"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-11-09",
            "original_text": "Can Low Volatility ETFs Protect Your Portfolio?",
            "features": {
                "keywords": [
                    "low volatility",
                    "ETFs",
                    "portfolio"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general finance"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-11-10",
            "original_text": "Notable ETF Inflow Detected - DGRO, PFE, ABBV, CMCSA",
            "features": {
                "keywords": [
                    "ETF inflow",
                    "DGRO",
                    "PFE",
                    "ABBV",
                    "CMCSA"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "diversified"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-11-11",
            "original_text": "Ex-Dividend Reminder: AmeriGas Partners, Bio-Techne and Pfizer",
            "features": {
                "keywords": [
                    "ex-dividend",
                    "AmeriGas Partners",
                    "Bio-Techne",
                    "Pfizer"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "energy",
                    "biotech",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-11-12",
            "original_text": "Vaccines Are an Important Growth Driver for Pfizer",
            "features": {
                "keywords": [
                    "vaccines",
                    "growth driver",
                    "Pfizer"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-11-13",
            "original_text": "Xeljanz: PFE’s Immunology and Inflammation Growth Driver",
            "features": {
                "keywords": [
                    "Xeljanz",
                    "PFE",
                    "immunology",
                    "inflammation",
                    "growth driver"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-11-14",
            "original_text": "New Clinical Oncology Collaboration Between Nektar and Pfizer to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with Avelumab and Talazoparib or Enzalutamide in Multiple Cancers",
            "features": {
                "keywords": [
                    "clinical oncology",
                    "Nektar",
                    "Pfizer",
                    "NKTR-214",
                    "Avelumab",
                    "Talazoparib",
                    "Enzalutamide"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-11-15",
            "original_text": "See what the IHS Markit Score report has to say about Pfizer Inc.",
            "features": {
                "keywords": [
                    "IHS Markit Score",
                    "report",
                    "Pfizer Inc."
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-11-16",
            "original_text": "Pfizer’s Eliquis Sees Double-Digit Revenue Growth Year-to-Date",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Eliquis",
                    "revenue growth"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-11-17",
            "original_text": "Nektar Therapeutics And Pfizer Enter Into New Clinical Oncology Collaboration",
            "features": {
                "keywords": [
                    "Nektar Therapeutics",
                    "Pfizer",
                    "clinical oncology",
                    "collaboration"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]